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The mechanisms involved in thyroid homeostasis are complex, and perfluoroalkyl substances 27 
(PFASs) have been indicated to interfere at several levels in this endocrine system. Disruption 28 
of the maternal thyroid homeostasis during early pregnancy is of particular concern, where 29 
subclinical changes in maternal thyroid hormones (THs) may affect embryonic and foetal 30 
development.  31 
The present study investigated associations between THs, thyroid binding proteins (TH-BPs) 32 
and PFAS concentrations in pregnant women from Northern Norway. 33 
Women participating in The Northern Norway Mother-and-Child contaminant Cohort Study 34 
(MISA) donated a blood sample at three visits related to their pregnancy and postpartum period 35 
(during the second trimester, 3 days and 6 weeks after delivery) in the period 2007-2009. 36 
Participants were assigned to quartiles according to PFAS concentrations during the second 37 
trimester and mixed effects linear models were used to investigate potential associations 38 
between PFASs and repeated measurements of THs, TH-BPs, thyroxin binding capacity and 39 
thyroid peroxidase antibodies (anti-TPO).  40 
Women within the highest perfluorooctane sulfonate (PFOS) quartile had 24% higher mean 41 
concentrations of thyroid stimulating hormone (TSH) compared to the first quartile at all 42 
sampling points. Women within the highest quartiles of perfluorodecanoate (PFDA) had 4% 43 
lower mean concentrations of triiodothyronine (T3) and women within the highest quartile of 44 
perfluoroundecanoate (PFUnDA) had 3% lower mean concentrations of free triiodothyronine 45 
(FT3). Further, the difference in concentrations and the changes between three time points were 46 
the same for the PFAS quartiles. Thyroxin binding capacity was associated with all the THs 47 
and TH-BPs, and was selected as a holistic adjustment for individual changes in TH 48 
homeostasis during pregnancy. Finally, adjusting for maternal iodine status did not influence 49 
the model predictions.  50 
Findings in the present study suggest modifications of TH homeostasis by PFASs in a 51 
background exposed maternal population. The variation in levels of THs between PFAS 52 
quartiles were within normal reference ranges and may not be of clinical significance in the 53 
pregnant woman. However, subtle individual changes in maternal THs may have significant 54 
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1. Introduction 85 
Thyroid hormones (THs) like thyroid stimulating hormone (TSH), thyroxin (T4) and 86 
triiodothyronine (T3), are involved in numerous physiological processes e.g. regulation of 87 
metabolism, bone remodelling, cardiac function and mental status in the adult. For the embryo 88 
and foetus, THs are crucial in all developmental stages. The onset of foetal thyroid function is 89 
at approximately 20 weeks gestation, and thus prior to this, maternal T4 is the sole source of 90 
TH to the developing foetal brain (Morreale De et al., 2004). In adults, THs are produced in the 91 
thyroid gland and transported to peripheral target tissues aided by thyroid hormone binding 92 
proteins (TH-BPs) e.g. thyroid binding globulin (TBG), transthyretin (TTR), and albumin. The 93 
thyroid function is regulated by negative feedback mechanisms, in which TSH stimulates the 94 
thyroid to synthesize T4 which is further converted to T3. TSH is in turn regulated by the 95 
hypothalamus as well as by the levels of circulating T3 and T4. In healthy individuals, serum 96 
levels of THs are maintained relatively stable with individuals having his or her specific set 97 
point (Feldt-Rasmussen et al., 1980).  98 
 99 
During the first two trimesters of pregnancy, marked changes are seen in the maternal 100 
hypothalamic pituitary (HTP) thyroid axis to increase the availability of THs. In short, these 101 
changes lead to a two- to three-fold increase in TBG production and a subsequent decrease in 102 
levels of free thyroxin (FT4) and free triiodothyronine (FT3) followed by an increased 103 
production of T3 and T4. The increase in T3 and T4 is less than the increase in TBG, resulting 104 
in a decreased T4/TBG ratio, creating a state of relative hypothyroxinemia. Hence, these 105 
adaptions mimic hyperthyroidism, but thyroid function per se does not change during 106 
pregnancy. There is uncertainty regarding reference ranges for thyroid tests during pregnancy 107 
as pregnancy-induced changes in thyroid physiology affects laboratory interpretation and 108 
presently no universally accepted reference ranges exist (Fitzpatrick and Russell, 2010). 109 
Changes in individual TH levels throughout pregnancy varies by gestational age, number of 110 
foetuses and study population, but generally, the woman achieves a new steady state in HTP 111 
function at the end of 2nd trimester which is maintained until delivery. After delivery, the 112 




Endocrine systems like the thyroid are susceptible to disruption by naturally-occurring and 115 
man-made compounds, possibly by affecting the hormone homeostasis through carrier proteins 116 
and receptors. One group of potential endocrine disrupting chemicals are poly- and 117 
perfluoroalkyl substances (PFASs). PFASs are persistent substances that have been directly 118 
emitted to the environment, intentionally or as by-products, during their production and use 119 
(Prevedouros et al., 2006). Diet is currently suspected to be the major on-going exposure 120 
pathway of PFASs for humans (Fromme et al., 2009; Haug et al., 2011a; Vestergren and 121 
Cousins, 2009). In addition, these chemicals are passed to humans through air, house dust, 122 
drinking water and water based beverages (Eschauzier et al., 2013; Haug et al., 2011a; Haug et 123 
al., 2011b; Ullah et al., 2011).  124 
 125 
Scientific and public concern regarding PFASs, are their potential to perturb maternal hormonal 126 
homeostasis and subsequently affect pregnancy outcome by increasing the risk of spontaneous 127 
abortions, placental disruptions, foetal distress, malformations, prematurity, decreased birth 128 
weight, and hypertension (Boas et al., 2012; Morreale De et al., 2000; Morreale De et al., 2004; 129 
Stahl et al., 2011). Disruption of the maternal thyroid homeostasis during early pregnancy is of 130 
particular concern, where subclinical changes in maternal THs may affect embryonic and foetal 131 
development (Boas et al., 2012). Compared to the wide population reference ranges for THs, 132 
the range of variation within each individual are narrower. Hence, subtle changes in the 133 
individual set point of thyroid homeostasis may have significant effects, especially if occurring 134 
during critical developmental periods (Feldt-Rasmussen et al., 1980).  135 
 136 
T3 and T4 are the only biological molecules which are halogenated (iodine). Similarly, PFASs 137 
are halogenated (fluorine) with active sites that resembles those of T3 and T4 (Preau et al., 138 
2014). When assessing effects of PFASs on TH homeostasis, the relevant mechanisms of 139 
disruption are; i) disturbance of the overall activity of the thyroid gland by interference with the 140 
TH receptors, ii) stimulation or inhibition of enzyme functions which mediates iodine uptake 141 
of the thyroid gland in the synthesis of T3 and T4, and iii) competitive displacement of THs on 142 
their binding proteins (Boas et al., 2012). Disruption of the thyroid function is often investigated 143 
in regards to hypothyroidism with the reporting of TSH concentrations. TSH levels can reflect 144 
mild thyroid functional impairment even when T4 and T3 concentrations are within normal 145 
ranges but hypothyroxinemia can still occur with normal TSH and T3 concentrations. Hence, 146 
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in the absence of assessment of the overall thyroid function; the clinical importance of 147 
individual TH levels is unclear (Braverman and Utiger, 1986). Therefore, the present study aims 148 
to investigate the overall thyroid function in relation to PFAS concentrations by investigating 149 
associations between all the THs (TSH, T3, T4, FT3, FT4), thyroxin binding capacity, anti-150 
thyroid peroxidase antibodies (anti-TPO), thyroid hormone binding proteins (TH-BPs) (TBG, 151 
TTR and albumin) at three time points; 2nd trimester of pregnancy, 3 days and 6 weeks after 152 
delivery and PFAS concentrations in women from Northern Norway.  153 
 154 
2. Materials and methods 155 
2.1 Study participants and collection of blood samples 156 
The selected subjects in the present study represent the 391 women who completed the Northern 157 
Norway Mother-and-Child Contaminant Cohort Study (MISA) which consists of 515 enrolled 158 
pregnant women, recruited from June 2007 to October 2009 (recruitment period; 867 days). All 159 
participants answered a detailed questionnaire about diet and lifestyle at enrolment, and donated 160 
a blood sample at three visits/time points related to their pregnancy (around gestational week 161 
18, 3 days and 6 weeks after delivery). Detailed information about the study group 162 
characteristics, ethical approvals, the food frequency questionnaire (FFQ) and the blood 163 
collection procedures have been reported elsewhere (Hansen et al., 2010; Veyhe et al., 2012).  164 
 165 
2.2 Chemical analyses 166 
2.2.1 PFAS analyses 167 
Blood samples donated at median gestational week 18 (ranging 10–34) were analysed for a 168 
variety of PFASs. A total of 26 PFASs were initially screened for in a sub-group of 50 serum 169 
samples. Compounds detected above the limit of detection (LOD) in more than 20% of the 170 
samples were further quantified in the remaining serum samples (N = 391). Detailed 171 
information about the compounds, sample preparation, extraction method, analytical method, 172 
reagents and instrumentation has been reported elsewhere (Berg et al., 2014; Hanssen et al., 173 
2013). Briefly, PFASs were determined in serum samples using sonication-facilitated liquid–174 
liquid extraction, activated ENVI-carb clean-up (Powley et al., 2005) and analysed by ultrahigh 175 




Quantification of the compounds was performed by the internal standard addition method with 178 
isotope-labeled PFASs (Hanssen et al., 2013). Further details regarding quality control have 179 
been reported elsewhere (Berg et al., 2014)  180 
 181 
2.2.2 TH and TH-BP analyses  182 
Determination of TH, TH-BP, thyroxin binding capacity and anti-TPO concentrations in non-183 
fasting serum samples from three visits (second trimester, 3 days and 6 weeks after delivery) 184 
were performed by laboratory staff at the University Hospital of Northern Norway, Department 185 
of Laboratory Medicine. The analyses are routine analyses used in the clinic for diagnostic 186 
purposes except for T3, T4 and thyroxin binding capacity. Details on the different methods, 187 
instrumentation, analytical variation and reference ranges are provided in Table S1 in the 188 
Supplemental Material. The laboratory is certified according to ISO 151810 (Norwegian 189 
accreditation, 2014) and all reagents, calibrators and equipment were CE-approved. Quality 190 
controls are run at three different concentrations every day and additionally the laboratory 191 
participates in the LabQuality external quality assessment program (Labquality Finland, 2014).  192 
 193 
2.3 Statistical analyses 194 
Statistical analyses were performed using SPSS statistic software, version 22 (IBM SPSS Inc. 195 
Chicago, IL, USA). Statistical significance was defined as p < 0.05. All PFAS, TH and TH-BP 196 
results were log-transformed in the statistical analyses. For PFASs, only compounds with 197 
detection frequencies above 80% were evaluated in statistical models where concentrations 198 
below LODs were replaced by LOD/√2 (Anda et al., 2007). Partial least square (PLS) 199 
regressions were used for data reduction and screening for important variables. Mixed effects 200 
linear models were used to investigate potential associations between PFASs and three repeated 201 
measurement of THs, where the pregnant women were assigned to quartiles according to PFAS 202 
concentrations in 2nd trimester. Separate models were built for five dependent variables; TSH, 203 
T3, T4, FT3 and FT4. PFAS quartiles and TH-BPs were included as fixed factors and 204 
covariates, respectively. A quadratic development over time was included as fixed factor in all 205 
the models. The variance of the fixed factors and the distribution of significant covariates were 206 
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homogeneous across PFAS quartiles. Diagnostic plots of the residuals and potential influential 207 
points were evaluated.    208 
 209 
3. Results: 210 
3.1 Population characteristics and PFAS concentrations 211 
The median age was 32 and the majority of the participants were nulliparous or primiparous 212 
(parity varied from 0-4), for the MISA study population. Further details on demographic 213 
characteristics are briefly presented in the Supplemental Material, Table S2 and described in 214 
detail elsewhere (Veyhe et al., 2012). Seven PFASs; pefluorohexane sulfonate (PFHxS), 215 
perfluoroheptane sulfonate (PFHpS), perfluorooctane sulfonate (PFOS), perfluorooctanoate 216 
(PFOA), perfluorononanoate (PFNA), perfluorodecanoate (PFDA) and perfluoroundecanoate 217 
(PFUnDA) were detected in more than 80% of blood samples and were included in the 218 
statistical analyses. PFOS (median of 8.03 ng/mL) was the dominating compound followed by 219 
PFOA (1.53 ng/mL), PFNA (0.56 ng/mL), PFHxS (0.44 ng/mL), PFUnDA (0.26 ng/mL), 220 
PFDA (0.23 ng/mL) and PFHpS (0.10 ng/mL). Spearman correlation coefficients showed high 221 
to moderate correlations between PFOS and PFOA (r=0.65), PFHxS, (r=0.63), PFHpS (r=0.68), 222 
PFNA (r=0.60), PFDA (r=0.57) and PFUnDA (r=0.45). The correlation between PFDA and 223 
PFUnDA was higher than between PFOS and any of these two compounds. PFAS 224 
concentrations and their predictors are described in detail in a previous publication (Berg et al., 225 
2014).  226 
 227 
3.2 Concentrations of THs and TH-BPs 228 
Concentrations and specific study group reference ranges of THs, TH-BPs and thyroxin binding 229 
capacity are provided in Table 1. Sixteen women were excluded from the study due to self-230 
reported thyroid related disease and/or use of medications. Further, 22, 15 and 15 women had 231 
thyroid peroxidase antibodies above 34 IU/L at visit 1, 2 and 3 respectively, and were 232 
categorized as anti-TPO positive according to the reference range applied by the manufacturer. 233 
The anti-TPO positive women were included in all analyses, tables and figures as they did not 234 
alter the variance in TH concentrations compared to anti-TPO negative women. The specific 235 
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study group reference range (2.5–97.5th percentile) for the THs were within the normal 236 









 of THs, TH-BPs, thyroxin binding capacity and anti-TPO, and study group spesific reference ranges at three repeated measurments
Compound Median (Range) AM SD Reference range
b
Median (Range) AM SD Reference range
b
Median (Range) AM SD Reference range
b
TSH (mlU/L) 1.55 (0.06-10.2) 1.76 1.04 0.44-4.48 2.37 (0.15-9.51) 2.56 1.20 0.98-5.39 1.39 (0.06-6.54) 1.55 0.80 0.47-3.38
T3 (nmol/L) 2.71 (1.47-4.75) 2.75 0.46 1.97-3.73 2.75 (1.32-4.66) 2.80 0.50 1.81-3.88 1.70 (1.15-2.53) 1.72 0.22 1.29-2.22
T4 (nmol/L) 145 (92.00-215) 146 21.1 111-190 144 (77.0-232) 145 26.3 97.1-204 97.0 (63.0-153) 98.5 14.3 72-130
FT3 (pmol/L) 4.59 (2.99-7.08) 4.62 0.53 3.66-5.79 4.50 (2.72-6.77) 4.52 0.57 3.50-5.73 4.63 (3.14-6.48) 4.66 0.45 3.80-5.77
FT4 (pmol/L) 13.0 (9.00-20.0) 13.4 1.62 10.0-17.0 13.0 (8.00-19.0) 13.0 1.87 10.0-17.0 14.0 (10.0-25.0) 14.3 1.74 12.0-18.0
TBG (mg/L) 36.7 (23.2-69.6) 37.2 6.74 26.2-53.3 37.0 (19.9-56.7) 37.3 6.35 25.2-51.4 17.9 (11.7-39.1) 18.4 3.44 12.9-26.54
TTR (g/L) 0.19 (0.09-0.27) 0.19 0.03 0.15-0.25 0.19 (0.09-0.42) 0.19 0.04 0.11-0.29 0.22 (0.13-0.38) 0.22 0.03 0.16-0.29
Albumin (g/L) 40.0 (33.9-47.4) 40.2 2.42 36.0-46.0 34.9 (24.3-46.4) 34.8 3.15 28.0-40.0 46.5 (40.9-53.6) 46.6 2.27 42.0-51.0
Thyroxin binding capacity 1.26 (0.84-1.50) 1.26 0.09 1.07-1.43 1.29 (0.20-1.50) 1.28 0.10 1.10-1.42 1.01 (0.50-1.18) 1.00 0.07 0.81-1.11
(TBI)
c
Positive > 34 IU/L % Positive > 34 IU/L % Positive > 34 IU/L %
Anti-TPO (IU/mL) 22 6 15 4 15 4
a
Anti-TPO positive women are included in medians. The same 15 women were anti-TPO positive at all three visits
b
Defined as the 2.5 percetile (lower range) and 97.5 percentile (upper range) for this population
c
Thyroxin binding index, the measure unit for thyroxin binding capacity
Visit 2: 3 days postpartum, N=372Visit 1: 2nd trimester, N= 375 Visit 3: 6 weeks postpartum, N= 374
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3.3 THs and associations to PFAS concentrations 241 
After adjusting for significant covariates such as parity, age, thyroxin binding capacity and 242 
BMI, and regardless of including anti-TPO positive women or not, TSH was positively 243 
associated with PFOS; T3 was negatively associated with PFDA; and FT3 was negatively 244 
associated with PFUnDA (Table 2). The significant covariates were included in the respective 245 
models (Table 2), but many more were evaluated (e.g. iodine sufficiency and gestational week) 246 
and are listed in Table S2 in the Supplemental material. Thyroxin binding capacity was 247 
significantly associated with all the thyroid hormones and the individual binding proteins, and 248 
was selected as a holistic adjustment for individual changes in thyroid hormone homeostasis 249 
during pregnancy and postpartum periods. Several PFASs (Results not presented) were 250 
inversely associated with T4 and FT4 after adjusting for age and BMI, but after including 251 
thyroxin binding capacity the associations were no longer significant. Further, adjusting for 252 
estimated daily dietary intakes of iodine (μg/day) and concentrations of iodine in urine (μg/L 253 
for 212 participants), did not influence the model predictions (results not presented) when 254 
grouped into iodine sufficient, mildly deficient and deficient, according to guidelines from the 255 
World Health Organisation (World Health Organization et al., 2014). 256 
 257 
Women in the highest PFOS quartile had higher mean concentration of TSH at all three time 258 
point compared to women in the first quartile (Figure 1 A and B). Similar, women in the highest 259 
PFDA and PFUnDA quartiles had lower T3 and FT3 concentrations, respectively (Figure 1 C, 260 
D and E, F). Further, the proportion of women with a depleted supply of T4/FT4 and T3/FT3 261 
(subclinical hypothyroidism), characterized by elevated TSH concentrations (>3.6 mlU/L) but 262 
with normal FT4 and FT3 concentrations (Fitzpatrick and Russell, 2010), increased for each 263 
PFOS quartile (Q1: n=12, Q2: n=16, Q3: n=24, Q4: n=30). Women in the extreme quartiles of 264 
PFHxS and PFOA had higher concentrations of TSH compared to the lowest quartiles, but when 265 
including PFOS concentration as a covariate, the associations were no longer significant (results 266 
not presented). PFDA weas negatively associated with FT3, but not after adjusting for PFUnDA 267 
(results not presented). Finally, the difference as well as the relative change in thyroid hormone 268 
concentrations over time was constant between PFAS quartiles (parallel growth curves, Figure 269 










Mixed-effects model estimated mean
a





Ŷ 95 % Confidence Interval р
Quartile 1: 0.3-5.7 N=94 Reference
Quartile 2:  5.8-8.0 N=90 0.18 0.06, 0.31 0.11
Quartile 3: 8.1-11.0 N=95 0.26 0.13, 0.40 0.03
Quartile 4: 11.1-35.9 N=96 0.35 0.21, 0.50 0.00
PFDA (ng/mL)
e
Ŷ 95 % Confidence Interval р
Quartile 1: 0.05-0.17 N=93 Reference
Quartile 2: 0.17-0.23 N=94 -0.04 -0.08, 0.04 0.46
Quartile 3: 0.23-0.31 N=94 -0.05 -0.08, 0.00 0.52





Ŷ 95 % Confidence Interval р
Quartile 1: LOD-0.15 N=92 Reference
Quartile 2: 0.16-0.25 N=94 -0.08 -0.15, -0.00 0.14
Quartile 3: 0.26-0-37 N=94 -0.09 -0.16, -0.01 0.23
Quartile 4: 0.4-0.96 N=95 -0.18 -0.25, -0.12 0.00
a
Mean differences in TH concentrations (Ŷ) are
 
backtransformed from log-estimates of fixed effect variables
b
Models are based on three measurements of THs per subject and included a subject-specific random intercept 
c
Coefficients express change for TSH concentrations across PFOS quartiles, with quartile 1 as the reference group
d
Parity and thyroxin binding capacity were included as covariates (fixed effects variables) in the model
e
Coefficients express change for T3 concentrations across PFDA quartiles, with quartile 1 as the reference group
f
Age, BMI and thyroxin binding capacity were included as covariates (fixed effects variables) in the model
g













Figure 1. TSH, T3 and FT3 concentrations for the PFAS quartiles at three sampling points, 278 
presented as boxplot (A, C and E) and as median concentrations (B, D and F).  279 
  280 
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4. Discussion: 281 
4.1 Associations between TH and PFAS concentrations  282 
The observed associations in our study suggest modifications of the thyroid homeostasis by 283 
PFASs in a background exposed maternal population. The results demonstrate higher TSH 284 
concentrations with higher PFOS concentrations in pregnant women. Women within the highest 285 
PFOS quartile had 24% higher mean TSH concentrations compared to the first quartile at all 286 
sampling points. These observations are in accordance with those in another pregnant 287 
population in Norway (Wang et al., 2013), where PFOS concentrations were positively 288 
associated to TSH concentrations. Furthermore, the proportion of woman being classified with 289 
subclinical hypothyroidism at visit 1 (2nd trimester) were higher with increasing PFOS 290 
concentrations in our study. Higher PFHxS and PFOA concentrations were associated to higher 291 
TSH concentrations, although not significantly when adjusting for PFOS concentrations. In 292 
comparison, PFHxS was positively associated to TSH levels but not to PFOS in a pregnant 293 
population from the Taiwan Maternal and Infant Cohort Study (Wang et al., 2014). The results 294 
indicate that PFOS can interfere with the production and elimination of T3 and T4, where 295 
elevated levels of TSH in women with high concentrations of PFOS could be the adjusted 296 
homeostasis state due to a reduction in T3 and T4. TSHs ability to maintain equilibrium in the 297 
TH homeostasis, may further explain that the variance in levels of T3 and T4 between PFOS 298 
quartiles were within the normal reference ranges in our study. In accordance with 299 
investigations carried out in rats, a single dose of PFOS caused a reduction in T3 and T4 levels 300 
(Chang et al., 2008).  301 
 302 
In the present study PFDA concentrations were inversely associated to T3, and the women 303 
within the highest quartiles had 4% lower concentrations compared to women in the first 304 
quartile at all sampling points. Similar, PFUnDA concentrations were inversely associated to 305 
FT3 where women within the highest quartile had 3% lower concentrations. To the best of our 306 
knowledge, inverse associations between longer chained PFASs and maternal serum T3 and 307 
FT3 levels have not been reported previously, whereas Wang et al. (2014) reported a significant 308 
association between PFDA and cord blood T3 levels. Presently, there are no reports on the 309 
mechanisms by which PFDA and PFUnDA might modify thyroid hormones in humans or 310 
animals, but in a study conducted on a rat pituitary tumour cell line expressing intracellular 311 
thyroid receptor (TR), PFDA and PFUnDA significantly decreased the T3-induced cell 312 
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proliferation (Long et al., 2013). The authors therefore believe that PFDA and PFUnDA might 313 
compete with T3 binding to TR. Considering the increasing temporal trends of longer chained 314 
PFASs in humans (Nost et al., 2014) their endocrine disrupting potencies are a growing concern 315 
and studies on thyroid disrupting effects of these longer chained PFASs are warranted.  316 
 317 
PFASs have been indicated to interfere at several levels of the thyroid homeostasis. We 318 
observed that PFASs were associated to individual TH set points but not to the relative change 319 
in TH levels across sampling period. The quartile differences in TH levels were consistent at 320 
all the time points with no interaction between time and quartiles, thus PFASs exert its effect 321 
in a constant matter. Further, we did not observe any associations between thyroxin binding 322 
capacity and PFOS, as was reported in the C8 health project (Knox et al., 2011) suggesting 323 
competitive displacement of T4 by PFOS on TH-BPs. This could be explained by elevated TH-324 
BP levels in pregnancy and a subsequent excess in thyroxin binding sites, which likely renders 325 
it difficult to detect any displacement of T4 by PFASs on TH-BPs in this study.  326 
 327 
Studies performed on pregnant women present conflicting results in regards to thyroid 328 
disrupting potencies of PFASs (Chan et al., 2011; Wang et al., 2013; Wang et al., 2014; Webster 329 
et al., 2014), whereas similar studies in animals demonstrate consistent physiological effects 330 
including disruption of thyroid hormone homeostasis (Fuentes et al., 2006; Lau et al., 2003; 331 
Thibodeaux et al., 2003). Different exposure histories in different populations may influence 332 
the associations between PFASs and THs as well as variation in lifestyle predictors such as 333 
parity, breastfeeding, birth year and study period that affect PFAS concentrations (Berg et al., 334 
2014). Hence, measurement of PFASs at one time point may not reflect the historic exposure 335 
to PFASs and potential early effects on thyroid function. Further, the human exposure scenario 336 
with lifelong exposure to a mixture of chemicals in low doses, the large physiological variation 337 
in TH levels between individuals and complicated pathways, render human effect studies more 338 
difficult to perform. Finally, TSH, T3 and T4 are tightly regulated within a given individual, 339 
where the expected inter-individual variations may camouflage differences associated with 340 
exposure.  341 
 342 
4.2 Study design and strengths 343 
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To the best of our knowledge, this is the first study investigating the effect of PFASs on ten 344 
thyroid hormone parameters, and we have also included three repeated measurements. Due to 345 
the complex thyroid system, assessment of potential thyroid impairment cannot be interpreted 346 
from individual TH levels only. Furthermore, T3 and T4 levels per se are not adequate hormone 347 
indicators in pregnant women (Glinoer and Spencer, 2010) due to the alterations in TH levels, 348 
blood composition and volume. To accompany this complexity we have adjusted for the 349 
increase in thyroxin binding capacity (reflects elevated levels of all the TH-BPs) as a proxy for 350 
the pregnancy related alterations in blood THs and TH-BPs in statistical models. We have also 351 
reported concentrations of FT3 and FT4 in addition to T3 and T4, as the evaluation of these are 352 
generally preferred in pregnant women due to that the increase in TH-BPs may mask an actual 353 
decrease in levels of T4 and T3. We have reported TSH levels as well because TSH reflects the 354 
thyroid status more directly, and can reveal abnormalities in T3 and T4 levels despite apparently 355 
normal levels of these THs (Glinoer and Spencer, 2010). Still, in a situation with a low supply 356 
of T4, normal T3 levels might prevent an increase in circulating TSH and consequently, 357 
hypothyroxinemia will not be detected if only TSH is measured (Braverman and Utiger, 1986). 358 
Further, as the thyroid homeostasis is dynamic and a single measurement may not adequately 359 
characterize the maternal thyroid function, we have reported repeated measurements of THs.  360 
 361 
In the present study, PFHxS, PFDA and PFUnDA were inversely associated to FT4 and T4. 362 
However, when adjusting for the levels of TH-BPs by including thyroxin binding capacity, 363 
associations were no longer observed. Consequently, had we not corrected for the influence of 364 
TH-BPs on TH levels, we would have reported significant associations between several PFASs 365 
and FT4/T4. This might explain why our observations are not in accordance to the most recent 366 
publication on PFASs and THs in a pregnant population (Wang et al., 2014), who reported 367 
PFUnDA to be significant inversely associated with FT4 and T4. That study did not report on 368 
adjustments for gestational week or elevated levels of TH-BPs. Further, due to differences in 369 
PFAS concentrations and sampling points during pregnancy, the results from the two studies 370 
may not be comparable. Hence, inconsistencies in analytes and covariates investigated may 371 
account for some of the discrepancies in observed relationships between PFASs and THs in 372 
different studies which complicate the conclusion on definite relations. 373 
 374 
4.3 Clinical relevance 375 
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Concentrations of all the THs varied within normal reference ranges and as the thyroid system 376 
is tightly regulated, small changes in TH concentrations will likely be adjusted for through the 377 
negative mechanisms which naturally secure TH equilibrium. Consequently, the indicated 378 
PFAS induced changes in TH concentrations, may not have caused clinical effects in the 379 
mother, thus the physiological importance of the observations is not established. Several studies 380 
have described ranges for thyroid hormone levels during pregnancy but have demonstrated 381 
variation by gestational age, number of foetuses, population studied, laboratory, and testing 382 
method (Fitzpatrick and Russell, 2010). In the present study, increasing levels of TSH according 383 
to increased PFOS concentrations may indicate low individual levels of T4 in these women. 384 
The specific reference ranges for T4 and FT4 in this study group were within the mid to high 385 
end of the normal reference ranges (Table 1 and Table S1), while the specific reference ranges 386 
for PFOS quartile four (results not presented) were within the lower end. Considering that levels 387 
of THs in pregnant women should be 40-100% higher than in non-pregnant (Blackburn, 2013), 388 
the subsequent distribution should have been towards the higher end of the reference range for 389 
the respective T4 and FT4 levels to be “normal”. Hence, the clinical relevance of individual 390 
levels might be masked in non-pregnant population reference ranges. 391 
 392 
Independent of the mode of action of PFASs on the maternal thyroid function and the 393 
subsequent clinical relevance, disruption of maternal TH homeostasis in any degree would only 394 
increase the difficulties encountered by the newborn in meeting postnatal hormone 395 
requirements (Morreale De et al., 2000). The foetus relies on maternal THs throughout gestation 396 
and a normal supply of maternal T4 has an important protective role also after midgestation. 397 
This is underlined by reports of poor developmental outcome e.g. impaired mental development 398 
and growth in babies faced with a premature interruption of the maternal supply of THs 399 
(Morreale De et al., 2000). Although the indicated PFAS induced changes in TH concentrations 400 
were within the reference ranges in the present study, small changes in THs may affect foetal 401 
development, especially if occurring during critical periods. Therefore, concerns have been 402 
raised regarding the effect of mild maternal thyroid hormone deficiency on foetal 403 
neurodevelopment. Decreases in childhood intellectual performance can occur even when a 404 
pregnant woman’s hypothyroidism is subclinical (mild and asymptomatic) where marginally 405 
low T4 levels in the pregnant woman cause reduction in cognitive functions of the offspring 406 
(Berbel et al., 2009; Haddow et al., 1999; Pop et al., 2003).. Hence, subtle changes in THs may 407 
have significant consequences for foetal health and consistent evidence confirms that disrupted 408 
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maternal thyroid homeostasis negatively affects newborn development (Morreale De et al., 409 
2000).  410 
 411 
4.4 Thyroid function and iodine  412 
The two principal causes of maternal hypothyroidism are iodine deficiency and exposure to 413 
xenobiotic thyroid disruptors. The negative health effects during pregnancy of thyroid 414 
hormones that have been associated to PFAS exposures, can resemble those related to iodine 415 
deficiency (eg. decreased maternal FT4 and increased maternal TSH, increased risk of 416 
prematurity, spontaneous abortion, and neurodevelopmental impairment) (Morreale De et al., 417 
2000; Morreale De et al., 2004; Stahl et al., 2011). Hence, the importance of assessing iodine 418 
status when investigating associations between thyroid disruptors and THs is obvious. In the 419 
present study, maternal iodine status did not influence the observed associations between 420 
PFASs and THs and was not included as a covariate in the final models. Still, iodine status may 421 
affect the variance in TH concentrations, as the degree of iodine sufficiency or deficiency 422 
affects individual TH set points and changes in concentrations throughout the pregnancy 423 
(Blackburn, 2013; Morreale De et al., 2004). For example, iodine deficient women may be more 424 
susceptible to TH disruption. This could not be observed in our cohort as the variation in iodine 425 
status was low. This is also important for the general population and emphasizes that iodine 426 
status may interact with PFAS effects on thyroid homeostasis. Still, the majority of studies are 427 
not considering iodine status in regards to thyroid disruptors.  428 
 429 
4.5 Mixture effects 430 
Although the statistical analyses investigate the relationship between one or several dependent 431 
and independent variables at the same time, contaminants do not occur isolated in the human 432 
blood circulation. This means that the actual causality between physiological processes and the 433 
impairment by contaminants is complicated by the complex correlation of exposures. Also, 434 
there might be interactions and dose dependencies that we are not able to capture. This is evident 435 
in the observation of PFOA, PFHxS and PFDA being significantly associated to THs in 436 
individual models, and where the associations were no longer significant when adjusting for 437 
dominant components such as PFOS. Due to the strong correlation between the contaminants 438 
and their joint explanation of the outcome, it was not possible to isolate the variance in THs 439 
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explained by PFOA, PFHxS or PFDA alone. A possible solution to this is to summarize 440 
contaminants based on similarities e.g. chemical properties, mode of action and emission 441 
patterns, and report mixture effects, but this is beyond the scope of this publication. For further 442 
progression in the research on contaminants and human health effects, it is important to assess 443 
multiple exposure scenarios. Therefore, in subsequent studies we aim to include several 444 
contaminants and thyroid related outcomes in the children, to assess associations of thyroid 445 
function with combined exposures.  446 
 447 
5. Conclusions 448 
Women with the highest concentrations of PFOS, PFDA and PFUnDA had consistently higher 449 
TSH and lower T3 and FT3 concentrations, respectively, at all sampling points compared to 450 
women with the lowest concentrations. The difference in concentrations and the changes 451 
between three time points were the same for the PFAS quartiles. Despite significant associations 452 
between PFASs and THs, TH levels were within normal reference ranges and may not be of 453 
clinical significance in the pregnant woman. However, the foetus relies on maternal THs 454 
throughout gestation and a normal supply of maternal T4 has an important protective role also 455 
after midgestation, hence, subtle individual changes in thyroid hormones may have significant 456 
consequences for foetal health. 457 
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Table S1
Analytical methods, instrumentation, analytical variation and reference ranges






ECLIA/Cobas 8000, e602 3.2 0.20-4.30 mlU/L
T3 ECLIA/Cobas 8000, e602 1.9 1.3-3.1 nmol/L
T4 ECLIA/Cobas 8000, e602 4.2 66-181 nmol/L
FT3
c.
ECLIA/Cobas 8000, e602 5.1 2.8-7.1 рmol/L
FT4
c
ECLIA/Cobas 8000, e602 3.6 9-22 pmol/L
Anti-TPO
c
ECLIA/Cobas 8000, e602 9.9 < 34 IU/ml
T-Uptake ECLIA/Cobas 8000, e602 4.8 0.8-1.3 TBI
TBG Chemiluminescence enzyme IA/IMMULITE 2000 7.5 47-45 mg/L
TTR
c
Immuneturbidimetry/Cobas 8000, c702 2.6 0.15-0.29 g/L
Albumin
c
Colometric assay (bromcresol green)/Cobas 8000, c702 1.9 39.7-49.4 g/L
a
The analystical variation is calculated from all samples run in the diagnostic routine in the year 2013, except for T3, T4,  TTR and




percentiles) are those recommended by the manufacturer (Roche) representing a healthy nonpregnant population, 
  except for TBG which is for pregnant women (third trimester)
c
The analysis is accreditated according to ISO standard 15189
Table S2 




Gestational week at visit 1 18 10-34
Sampling time visit 2 (Days after delivery) 3 1-13
Sampling time visit 3 (Weeks after delivery) 7 3-24
Prepregnancy BMI 23 18-44
BMI at visit 1 25 18-43
BMI at visit 2 27 18-45
BMI at visit 3 24 17-40
Education: Years in school 16 8-20
Thyroxin binding capacity (T-uptake) Table S1 -
TBG Table S1 -
TTR Table S1 -
Albumin Table S1 -




Alchohol during pregnancy Yes/No -
Smoking Yes/no -
a
Participants were categorized as iodine sufficient according to a prepregnancy dietary
  intake of iodine above 150 μg/d (manuscript in preparation by Hansen et al.)
b
Participants were categorized as iodine sufficient according to concentrations of 
  iodine in urine above 150 μg/L (manuscript in preparation by Hansen et al.)
